Company profile: EndoTex
1.1 - Company Overview
Company description
- Provider of less-invasive medical devices for use in the vascular system, offering solutions for treating carotid artery disease. Focused on development and manufacturing; founded in 1995 and based in Cupertino, California.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to EndoTex
Abliva
HQ: Sweden
Website
- Description: Provider of medicines for primary mitochondrial diseases—congenital, rare and often severe conditions resulting from mitochondrial dysfunction. Portfolio spans early discovery to clinical phases. Pipeline includes KL1333 to address symptoms such as chronic fatigue and muscle weakness, and NV354 for diseases with neurological complications, including Leigh syndrome and MELAS.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Abliva company profile →
Blackrock Neurotech
HQ: United States
Website
- Description: Provider of brain-computer interface technology and manufacturing, offering implantable clinical solutions and tools including the Utah Array for neural recording and stimulation; NeuroPort BCI to control prosthetics and regain motor functions; Wireless iBCI for high-bandwidth remote neural signals; and a cortical neuroprosthetic that provides artificial vision via neural stimulation.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Blackrock Neurotech company profile →
Quadrant Biosciences
HQ: United States
Website
- Description: Provider of epigenetic diagnostics focused on early detection of neurological disorders, offering: a virtual pediatric clinic for autism evaluations via telehealth; molecular diagnostics for COVID-19, autism and Parkinson’s; autism assessment workflow software; and wastewater monitoring for SARS-CoV-2 and other pathogens.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Quadrant Biosciences company profile →
Vitro Biopharma
HQ: United States
Website
- Description: Provider of stem cell therapy, cell lines, and cell culture media, including AlloRx Stem Cell therapy from Wharton’s jelly–derived MSCs for autoimmune and inflammatory disorders; MSC-Gro specialty media for MSC growth and expansion; research-grade cancer-associated and native fibroblasts; human umbilical cord and placenta-derived MSC lines; and MSC-Gro formulations (low serum, serum-free, CAF-specific).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vitro Biopharma company profile →
Neuron Bio
HQ: Spain
Website
- Description: Provider of innovative biosolutions: AlzTEST blood biomarker diagnostic for Alzheimer’s; Omega-3 DHA microalgae oil for functional foods and nutraceuticals; MicroBiOil platform for microbial oils and oleochemicals; Microbiotools by Neol for bioprocess development; custom R&D in biomedicine, toxicology and agro-food; and a drug discovery platform for neurodegenerative diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Neuron Bio company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for EndoTex
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to EndoTex
2.2 - Growth funds investing in similar companies to EndoTex
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for EndoTex
4.2 - Public trading comparable groups for EndoTex
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →